French Aerospace & Defense Stock News

ENXTPA:ETL
ENXTPA:ETLMedia

Eutelsat Talks With ISRO Put India Focus And Valuation In Spotlight

Eutelsat Communications is in talks with India's space agency ISRO about using its rockets for future satellite launches. The discussions focus on expanding launch options and deepening access to the Indian market. The potential partnership comes as India’s space sector continues to open up to commercial activity. Eutelsat Communications (ENXTPA:ETL) is exploring these talks while its shares trade around €2.045. The stock has seen a 14.5% gain year to date, but remains down 34.0% over 1...
ENXTPA:SU
ENXTPA:SUElectrical

Schneider Electric Extends Wireless And Autonomous Reach While Valuation Signals Mixed Clues

Schneider Electric (ENXTPA:SU) has joined the Thread Group's Board of Directors, taking an active role in shaping the wireless networking standard for smart buildings and energy management. The company has also released research on growing momentum toward autonomous and self optimising operations in the energy and chemicals sector. These developments highlight Schneider Electric's expanding influence in digital infrastructure and industrial automation technologies. For investors tracking...
ENXTPA:TKO
ENXTPA:TKOCapital Markets

Tikehau Capital’s Energy Transition Focus Spurs Fresh Look At Valuation

Tikehau Capital (ENXTPA:TKO) is drawing attention as fund managers highlight its focus on energy transition and energy security assets, particularly manufacturers of critical equipment and local infrastructure solutions that attract capital-intensive clean energy funding. See our latest analysis for Tikehau Capital. The recent focus on energy transition and energy security sits against a mixed performance backdrop, with a 2.9% 7 day share price return, a 16.0% 30 day share price decline, and...
ENXTPA:NANO
ENXTPA:NANOBiotechs

Nanobiotix Lung Cancer Trial Data Support Re Rating And Key Catalysts

Nanobiotix reported first clinical data from the Johnson & Johnson sponsored Phase 2 CONVERGE trial of JNJ-1900 (NBTXR3) in stage 3 inoperable non small cell lung cancer. Results presented at a major conference showed initial signals of efficacy alongside an acceptable safety profile. The data mark the first readout from a pivotal trial of Nanobiotix’s lead asset in this lung cancer setting. For investors watching ENXTPA:NANO, this update lands after a period of strong share price...
ENXTPA:PUB
ENXTPA:PUBMedia

Publicis Groupe Puts Kekst CNC’s AI And Cyber Counsel Center Stage

Kekst CNC, a Publicis Groupe subsidiary, has appointed Lyndsey Estin as Co-CEO to lead U.S. operations. The move highlights Publicis Groupe’s focus on advanced communications capabilities in areas such as AI and cybersecurity. For investors tracking ENXTPA:PUB, this shift at Kekst CNC sits squarely in the core of Publicis Groupe’s communications and advisory activities. Kekst CNC is a global communications arm, and its work spans crisis counsel and complex corporate issues that many large...
ENXTPA:VU
ENXTPA:VUElectronic

European Growth Companies With High Insider Ownership

In the current European market, investor sentiment is being shaped by geopolitical uncertainties and fluctuating energy prices, with indices like the STOXX Europe 600 showing modest gains amid these challenges. As economic conditions remain unpredictable, growth companies with high insider ownership can offer a unique appeal due to their potential for alignment between management and shareholder interests, which may be particularly valuable in navigating complex market environments.
ENXTPA:ABVX
ENXTPA:ABVXBiotechs

A Look At Abivax (ENXTPA:ABVX) Valuation After Wider Losses Trial Progress And Index Inclusion

ABIVAX Société Anonyme (ENXTPA:ABVX) is in focus after full year 2025 earnings showed revenue of €4.57 million and a net loss of €336.1 million, alongside fresh trial, leadership, financing, and index inclusion updates. See our latest analysis for ABIVAX Société Anonyme. The recent earnings release, positive Phase 3 safety update, leadership hires, ESOP related shelf registration, and FTSE All World Index inclusion come against a backdrop of a 1 year total shareholder return above 10x. At the...
ENXTPA:AIR
ENXTPA:AIRAerospace & Defense

Is It Time To Reconsider Airbus (ENXTPA:AIR) After Recent Share Price Weakness

If you are wondering whether Airbus is fairly priced or offering value at current levels, it helps to start with how its market performance lines up against underlying worth. The share price recently closed at €159.18, with returns of a 4.3% decline over 7 days, a 13.6% decline over 30 days, a 21.9% decline year to date, and around 0.0% over the last year, compared with 34.1% over 3 years and 69.6% over 5 years. Recent headlines around Airbus have focused on its role as a key aerospace and...
ENXTPA:RF
ENXTPA:RFDiversified Financial

Eurazeo Index Exit Puts Focus On Active Sentiment And Future Upside

Eurazeo (ENXTPA:RF) has been removed from the FTSE All-World Index. The change affects the stock’s presence in a major global equity benchmark tracked by index funds and ETFs. This type of index action can influence trading activity and how institutional investors view the company. Eurazeo is a listed investment company with exposure to private equity style assets, which means its share often sits on the radar of global fund managers. Being dropped from a widely followed index such as the...
ENXTPA:OVH
ENXTPA:OVHIT

European Growth Stocks With High Insider Ownership For March 2026

As the European markets navigate through uncertainties spurred by geopolitical tensions and energy price fluctuations, investor sentiment remains cautious yet discerning. In such a climate, growth companies with high insider ownership often stand out as potentially resilient investments due to the alignment of interests between insiders and shareholders, which can be particularly advantageous during periods of economic volatility.
ENXTPA:BOL
ENXTPA:BOLOil and Gas

Assessing Bolloré (ENXTPA:BOL) Valuation After The Exceptional €1.5 Per Share Dividend Proposal

Bolloré (ENXTPA:BOL) has drawn fresh attention after its board proposed an exceptional €1.5 per share dividend, about €4.2b, alongside 2025 results and a regular €0.08 per share dividend plan. See our latest analysis for Bolloré. The exceptional dividend proposal and 2025 earnings release have arrived after a mixed period, with a 3.96% three month share price return, a 1.17% year to date share price gain, but a 1 year total shareholder return decline of 11.46%, suggesting short term momentum...
ENXTPA:SAN
ENXTPA:SANPharmaceuticals

Sanofi Pipeline Milestones Sharpen Focus On Specialty Growth Potential

Sanofi received FDA Breakthrough Therapy designation for oral venglustat targeting neurological symptoms in type 3 Gaucher disease. Sanofi reported positive phase 3 results for amlitelimab in atopic dermatitis. European regulators issued a positive opinion for Sarclisa subcutaneous with an on body injector for multiple myeloma, potentially introducing dual administration modes in the EU. Sanofi, traded as ENXTPA:SAN, is currently priced at €81.99 and has seen a 5.4% gain over the past week,...
ENXTPA:ABVX
ENXTPA:ABVXBiotechs

Is It Time To Reassess Abivax (ENXTPA:ABVX) After The Recent Share Price Pullback

If you are wondering whether ABIVAX Société Anonyme is priced attractively right now, the starting point is to compare what you pay today with what the business could be worth under different valuation lenses. The stock last closed at €89.20, after a 7 day return of an 18.5% decline and a 30 day return of a 13.1% decline, set against a very large 1 year gain and an 11.8x return over 3 years. Recent attention on ABIVAX Société Anonyme has been shaped by ongoing coverage of its position in the...
ENXTPA:IPN
ENXTPA:IPNPharmaceuticals

Assessing Ipsen (ENXTPA:IPN) Valuation After New Preclinical Oncology Data At AACR

Ipsen (ENXTPA:IPN) has come into focus after presenting fresh preclinical data at the AACR congress for two first in class oncology candidates, IPN01203 and IPN60300, targeting difficult solid tumor indications. See our latest analysis for Ipsen. The latest oncology data and recent conference activity come at a time when Ipsen’s share price has reached €157.7, with recent momentum reflected in a 90 day share price return of 32.97% and a 1 year total shareholder return of 48.68%. This...
ENXTPA:HO
ENXTPA:HOAerospace & Defense

Thales Dominican E Passport Deal Highlights Growing Digital Identity Role

Thales has partnered with the Dominican Republic to launch the country's first electronic passport, integrating advanced cybersecurity for citizen data. The project establishes a secure e-passport system and ongoing cyber threat monitoring for the Dominican Republic's border and identity infrastructure. For investors tracking ENXTPA:HO, this agreement adds additional real world evidence of Thales' role in digital identity and security, alongside its existing defense and aerospace...
ENXTPA:EL
ENXTPA:ELMedical Equipment

Is EssilorLuxottica (ENXTPA:EL) Starting To Look Interesting After Recent Share Price Slide

Wondering whether EssilorLuxottica Société anonyme is starting to look attractively priced, or if the recent share price leaves little margin for error. The stock last closed at €194.80, with returns of 0.0% over 7 days, a 17.8% decline over 30 days, a 26.6% decline year to date, and a 25.8% decline over 1 year, set against gains of 23.8% over 3 years and 52.1% over 5 years. Recent moves in the share price sit against a backdrop of ongoing interest in the business and its role in the global...
ENXTPA:AC
ENXTPA:ACHospitality

Assessing Accor (ENXTPA:AC) Valuation After Recent Share Price Pullback

How Accor’s Recent Share Performance Frames Today’s Setup Accor (ENXTPA:AC) has seen its share price fall about 17% over the past month and about 15% over the past 3 months, putting the hotel group’s current valuation and fundamentals back in focus for investors. See our latest analysis for Accor. That recent 17% 1 month share price decline sits against a 1 year total shareholder return of about a 3% decline and a 3 year total shareholder return of about 48%. This suggests shorter term...